A real-world data study of the effect of co-solvent differences on the clinical safety of melphalan for injection
EVOMELA<sup>®</sup> appears to demonstrate better efficacy and safety compared to PG-Mel; nonetheless, considering the study's limitations, these observations warrant further rigorous investigation to confirm their validity.
Authors
- Li Huang (ORCID: https://orcid.org/0000-0003-3910-3982)
- Wenming Chen
- Guorong Wang (ORCID: https://orcid.org/0000-0001-9163-8322)
- Jianzhou Yan
- Chenwei Zuo
Institutions
- China Pharmaceutical University (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Beijing Chaoyang Emergency Medical Center (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-09-26
- DOI
- https://doi.org/10.3389/fmed.2025.1554818
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China